The supercoiled round (SC) topology type of plasmid DNA has been regarded to be advantageous over open round or linearized analogue in transfection and expression effectivity, and due to this fact are largely demanded within the biopharmaceutical manufacturing. Nevertheless, manufacturing of high-purity SC plasmid DNA would lead to excessive manufacturing value. The impact of SC proportion in plasmid DNA on the standard of packaged lentiviral vectors has by no means been reported. On this research, we established an environment friendly system for manufacturing of high-titer lentiviral vectors utilizing suspension HEK293SF cells in serum-free media, and the lentiviral titer was not related to the proportion of SC plasmid DNA.
Plasmids DNA with totally different proportion of SC, open-circular, and linearized kinds have been ready utilizing the thermal denaturation technique, and have been transfected to adherent HEK293T or suspension HEK293SF cells for packaging of lentiviral vectors. The titer of lentiviral vectors from HEK293T cells, however not from HEK293SF cells, was considerably impaired when the proportion of SC plasmid DNA decreased from 60-80% to 30-40%. Additional lower of SC plasmid proportion to three% led to a dramatic discount of lentiviral titer irrespective of the packaging cell line was.
Nevertheless, lentiviral vectors from HEK293SF cells nonetheless confirmed a excessive titer even when the proportion of SC plasmid DNA was 3%. This research demonstrated that extraordinarily excessive proportion of SC plasmid DNA was not required for packaging of high-titer lentiviral vector in HEK293SF cells, a minimum of underneath our manufacturing course of.
Improvement of a Plasmid Shuttle Vector System for Genetic Manipulation of Chlamydia psittaci
The obligate intracellular bacterium Chlamydia psittaci is a identified avian pathogen inflicting psittacosis in birds and is able to zoonotic transmission. In human pulmonary infections, C. psittaci could cause pneumonia related to vital mortality if inadequately identified and handled. Though intracellular C. psittaci manipulates host cell organelles for its replication and survival, it has been troublesome to display host-pathogen interactions in C. psittaci an infection because of the lack of easy-to-handle genetic manipulation instruments. Right here, we present the genetic transformation of C. psittaci utilizing a plasmid shuttle vector that incorporates a controllable gene induction system.
The 7,553-bp plasmid p01DC12 was ready from the nonavian C. psittaci pressure 01DC12. We constructed the shuttle vector pCps-Tet-mCherry utilizing the complete sequence of p01DC12 and the 4,449-bp fragment of Chlamydia trachomatis shuttle vector pBOMB4-Tet-mCherry. pCps-Tet-mCherry contains genes encoding the inexperienced fluorescent protein (GFP), mCherry, and ampicillin resistance (AmpR). Goal genes will be inserted at a a number of cloning website (MCS). Importantly, these genes will be regulated by a tetracycline-inducible (tet) promoter.
Utilizing the pCps-Tet-mCherry plasmid shuttle vector, we present the expression of GFP, in addition to the induction of mCherry expression, in C. psittaci pressure 02DC15, which belongs to the avian C. psittaci 6BC clade. Moreover, we demonstrated that pCps-Tet-mCherry was stably retained in C. psittaci transformants. Thus, our C. psittaci plasmid shuttle vector system represents a novel focused method that allows the elucidation of host-pathogen interactions.
Psittacosis, brought on by avian C. psittaci, has a serious financial impression within the poultry business worldwide and represents a big danger for zoonotic transmission to people. Prior to now decade, the instruments of genetic manipulation have been improved for chlamydial molecular research. Whereas a number of genetic instruments have been primarily developed in Chlamydia trachomatis, a secure gene-inducible shuttle vector system has to not date been accessible for C. psittaci On this research, we tailored a C. trachomatis plasmid shuttle vector system to C. psittaci
We constructed a C. psittaci plasmid spine shuttle vector referred to as pCps-Tet-mCherry. The assemble expresses GFP in C. psittaci Importantly, exogeneous genes will be inserted at an MCS and are regulated by a tet promoter. The appliance of the pCps-Tet-mCherry shuttle vector system permits a promising new method to research unknown gene features of this pathogen.
Detection of A number of Transgene Fragments in a Mouse Mannequin of Gene Doping Primarily based on Plasmid Vector Utilizing TaqMan-qPCR Assay
The World Anti-Doping Company has prohibited gene doping within the context of progress in gene remedy. There’s a danger that the augmentation of genes utilizing plasmids may very well be utilized for gene doping. Nevertheless, no gold commonplace technique to detect this has been established. Right here, we aimed to develop a way to detect a number of transgene fragments as proof of gene doping. Firstly, gene supply mannequin mice as a mimic of gene doping have been created by injecting firefly luciferase plasmid with polyethylenimine (PEI) into the belly cavity.
The outcomes confirmed profitable institution of the mannequin, with ample luminescence upon in vivo imaging. Subsequent, a number of transgene fragments within the mannequin have been detected in plasma cell-free (cf)DNA, blood-cell-fraction DNA, and stool DNA utilizing the TaqMan- quantitative real-time PCR(qPCR) assay, with the very best ranges in plasma cfDNA. Utilizing only a single drop of complete blood from the mannequin, we additionally tried long-term detection.
c-Myc(MYC275) Antibody |
|||
| BNC800275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF680 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC800699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF680 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC800699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF680 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC810275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF680R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC810275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF680R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC810699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF680R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC810699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF680R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC810909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF680R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC810909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF680R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC940275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF594 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC940275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF594 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC940699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF594 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC940699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF594 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC940909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF594 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC940909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF594 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC700275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF770 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC700275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF770 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC700699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF770 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC700699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF770 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC700909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF770 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC700909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF770 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC880699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF488A conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC880699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF488A conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC880909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF488A conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC880909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF488A conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC050699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF405M conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC050699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF405M conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC050909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF405M conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC050909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF405M conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC040699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF405S conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC040699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF405S conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC040909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF405S conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC040909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF405S conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC430275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF543 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC430275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF543 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC400275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF640R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC400275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF640R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC400699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF640R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC400699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF640R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC400909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF640R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC400909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF640R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC050275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF405M conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC050275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF405M conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCB0275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), Biotin conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCB0275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), Biotin conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCB0699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), Biotin conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCB0699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), Biotin conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCAP0909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCAP0909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCA0909-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against c-Myc(MYC909), APC conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCAP0275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCAP0275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCAP0699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCAP0699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCB0909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), Biotin conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCB0909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), Biotin conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC880275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF488A conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC880275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF488A conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCR0275-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against c-Myc(MYC275), RPE conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCR0699-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against c-Myc(MYC699), RPE conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCR0909-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against c-Myc(MYC909), RPE conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCP0275-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against c-Myc(MYC275), PerCP conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCP0699-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against c-Myc(MYC699), PerCP conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCP0909-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against c-Myc(MYC909), PerCP conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNUM0275-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against c-Myc(MYC275), 1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNUM0699-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against c-Myc(MYC699), 1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNUM0909-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against c-Myc(MYC909), 1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCH0909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNCH0909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNUB0909-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against c-Myc(MYC909), Concentration: 0.2mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNUB0909-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against c-Myc(MYC909), Concentration: 0.2mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCH0275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNCH0275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCH0699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNCH0699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNUB0275-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against c-Myc(MYC275), Concentration: 0.2mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNUB0275-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against c-Myc(MYC275), Concentration: 0.2mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNUB0699-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against c-Myc(MYC699), Concentration: 0.2mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNUB0699-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against c-Myc(MYC699), Concentration: 0.2mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC040275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF405S conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC040275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF405S conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC550275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF555 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC550275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF555 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC550699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF555 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC550699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF555 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC610275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF660R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC610275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF660R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC610699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF660R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC610699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF660R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC610909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF660R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC610909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF660R conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC680275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF568 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC680275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF568 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC470275-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF647 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC275) Antibody |
|||
| BNC470275-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC275), CF647 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC470699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF647 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC470699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF647 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC550909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF555 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC550909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF555 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC430699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF543 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC430699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF543 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC430909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF543 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC430909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF543 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC680699-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF568 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC699) Antibody |
|||
| BNC680699-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC699), CF568 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC680909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF568 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC680909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF568 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC470909-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF647 conjugate, Concentration: 0.1mg/mL |
|||
c-Myc(MYC909) Antibody |
|||
| BNC470909-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against c-Myc(MYC909), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Polyclonal MYC / c-Myc Antibody (aa25-74) |
|||
| APR02915G | Leading Biology | 0.05ml | EUR 580.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human MYC / c-Myc (aa25-74). This antibody is tested and proven to work in the following applications: |
|||
Monoclonal MYC / c-Myc Antibody (aa408-420) |
|||
| AMM02198G | Leading Biology | 0.05mg | EUR 580.8 |
|
Description: A Monoclonal antibody against Human MYC / c-Myc (aa408-420). The antibodies are raised in Mouse. This antibody is applicable in IHC-P, E |
|||
Polyclonal MYC / c-Myc Antibody (aa386-435) |
|||
| APR02947G | Leading Biology | 0.05ml | EUR 580.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human MYC / c-Myc (aa386-435). This antibody is tested and proven to work in the following applications: |
|||
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| 20-abx137079 | Abbexa |
|
|
Myc Proto-Oncogene Protein (c-MYC) Antibody |
|||
| abx231791-100ug | Abbexa | 100 ug | EUR 661.2 |
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| abx139766-01mg | Abbexa | 0.1 mg | EUR 460.8 |
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| 20-abx133153 | Abbexa |
|
|
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| 20-abx133248 | Abbexa |
|
|
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| 20-abx133250 | Abbexa |
|
|
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| 20-abx133912 | Abbexa |
|
|
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| 20-abx118000 | Abbexa |
|
|
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| abx448567-100ug | Abbexa | 100 ug | EUR 627.6 |
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| abx448568-100ug | Abbexa | 100 ug | EUR 627.6 |
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| abx022462-02mg | Abbexa | 0.2 mg | EUR 627.6 |
Myc Proto-Oncogene (c-Myc Peptide) Antibody |
|||
| abx022463-02mg | Abbexa | 0.2 mg | EUR 610.8 |
Myc Proto-Oncogene (C-Myc Peptide) Antibody |
|||
| abx023934-100ug | Abbexa | 100 ug | EUR 376.8 |
Myc Proto-Oncogene (C-Myc Peptide) Antibody |
|||
| abx023935-01ml | Abbexa | 0.1 ml | EUR 376.8 |
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| abx018354-100ug | Abbexa | 100 ug | EUR 594 |
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| abx037911-100ug | Abbexa | 100 ug | EUR 469.2 |
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| abx413504-01mg | Abbexa | 0.1 mg | EUR 760.8 |
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| abx413821-1mg | Abbexa | 1 mg | EUR 994.8 |
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| abx413825-2mg | Abbexa | 2 mg | EUR 1830 |
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| abx413826-01mg | Abbexa | 0.1 mg | EUR 493.2 |
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| abx413829-20ug | Abbexa | 20 ug | EUR 326.4 |
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| 20-abx008959 | Abbexa |
|
|
Myc Proto-Oncogene Protein (c-Myc) Antibody |
|||
| 20-abx008960 | Abbexa |
|
|
Myc Antibody |
|||
| abx242911-100ul | Abbexa | 100 ul | EUR 477.6 |
Myc antibody |
|||
| 10R-10451 | Fitzgerald | 100 ug | EUR 522 |
|
Description: Mouse monoclonal Myc antibody |
|||
MYC antibody |
|||
| 10R-10606 | Fitzgerald | 100 ug | EUR 418.8 |
|
Description: Mouse monoclonal MYC antibody |
|||
MYC antibody |
|||
| 10R-1757 | Fitzgerald | 100 ug | EUR 614.4 |
|
Description: Mouse monoclonal MYC antibody |
|||
Myc antibody |
|||
| 10R-4914 | Fitzgerald | 100 ul | EUR 871.2 |
|
Description: Mouse monoclonal Myc antibody |
|||
Myc antibody |
|||
| 10R-4915 | Fitzgerald | 100 ul | EUR 829.2 |
|
Description: Mouse monoclonal Myc antibody |
|||
Myc antibody |
|||
| 10R-4916 | Fitzgerald | 100 ul | EUR 829.2 |
|
Description: Mouse monoclonal Myc antibody |
|||
Myc antibody |
|||
| 10R-7246 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Mouse monoclonal Myc antibody |
|||
Myc antibody |
|||
| 20R-1901 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Rabbit polyclonal Myc antibody |
|||
Myc antibody |
|||
| 20R-1902 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Rabbit polyclonal Myc antibody |
|||
Myc antibody |
|||
| 20R-1903 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Rabbit polyclonal Myc antibody |
|||
Myc antibody |
|||
| 20R-2131 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Rabbit polyclonal Myc antibody |
|||
Myc antibody |
|||
| 20R-2218 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Rabbit polyclonal Myc antibody |
|||
Myc antibody |
|||
| 20R-2219 | Fitzgerald | 50 ug | EUR 337.2 |
|
Description: Rabbit polyclonal Myc antibody |
|||
The outcomes confirmed that a number of transgene fragments have been detected till 11 days. These findings point out that the mix of plasma cfDNA or only one drop of complete blood with TaqMan-qPCR assay is possible to detect plasmid-PEI-based gene doping. Our findings may speed up the event of strategies for detecting gene doping in people.